Leukaemia Trial, Recruiting (NCT07019155)

Leukaemia Trial, Recruiting NCT07019155 Sponsor: National Cancer Institute (NCI) Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT07019155 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are older than 1 month of age.
People who have a history of changes or abnormalities affecting the DDX41 gene, DDX41 RNA, or DDX41 protein (this applies to Cohorts 1 and 2), OR people who have a history of changes or abnormalities in a different gene linked to a condition called Hereditary Hematologic Malignancy (HHM) (Cohort 3), OR people who do not have these gene changes themselves but have a close family member (parent, child, sibling, grandparent, aunt, uncle, niece, or nephew) who has been confirmed or is suspected to have one of these gene changes (Cohort 4).
People who have a doctor or healthcare provider outside of the NIH (the research institution running this trial) who is responsible for their ongoing care.
People who are able to understand and sign a written consent form — or, for children, whose parent or guardian is able to do so on their behalf.

Who may not be able to join:

No exclusion criteria have been listed for this trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sung-Yun Pai, M.D., National Cancer Institute (NCI)

Phone: (240) 781-4037

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07019155

Sponsor: National Cancer Institute (NCI)

Phase: Not Applicable

Status: Recruiting

Condition: Leukaemia

Trial contact: (240) 781-4037

More information: https://clinicaltrials.gov/study/NCT07019155

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are older than 1 month of age.
People who have a history of changes or abnormalities affecting the DDX41 gene, DDX41 RNA, or DDX41 protein (this applies to Cohorts 1 and 2), OR people who have a history of changes or abnormalities in a different gene linked to a condition called Hereditary Hematologic Malignancy (HHM) (Cohort 3), OR people who do not have these gene changes themselves but have a close family member (parent, child, sibling, grandparent, aunt, uncle, niece, or nephew) who has been confirmed or is suspected to have one of these gene changes (Cohort 4).
People who have a doctor or healthcare provider outside of the NIH (the research institution running this trial) who is responsible for their ongoing care.
People who are able to understand and sign a written consent form — or, for children, whose parent or guardian is able to do so on their behalf.

Who may not be able to join:

No exclusion criteria have been listed for this trial.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

National Cancer Institute (NCI)

Registry

ClinicalTrials.gov

Start date

24 July 2025

Est. completion

15 June 2035

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To estimate the EFS in individuals with DEAD-box helicase 41 (DDX41) aberrations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov